NCT02878785View on ClinicalTrials.gov

Decitabine and Talazoparib in Untreated AML and R/R AML

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

January 5, 2020

Study Completion Date

November 19, 2020

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Decitabine

DNA methyltransferase inhibitor

DRUG

talazoparib

poly ADP ribose polymerase (PARP) inhibitor

Trial Locations (1)

21201

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Van Andel Research Institute

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT02878785 - Decitabine and Talazoparib in Untreated AML and R/R AML | Biotech Hunter | Biotech Hunter